|
advertisement
|
|
|
|
| Healthcare IT and Biotechnology News Release |
| News Home :: Healthcare IT and Biotechnology News Releases :: More News Releases on this day |
| Date of Publication: Wednesday, July 02, 2008 |
Invitrogen and the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre Announce Collaboration to Advance Pharmacogenomics Research |
| A scientific collaboration aimed at advancing pharmacogenomics research through the development of novel methodologies and advanced reagents for targeted medical resequencing was announced today by Invitrogen Corporation. |
CARLSBAD, Calif. & MONTREAL -- A scientific collaboration aimed at advancing pharmacogenomics research through the development of novel methodologies and advanced reagents for targeted medical resequencing was announced today by Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre, a provider of pharmacogenomics research, content, and services.
The potential impact of pharmacogenomics, the study of how genetic variations impact a patient’s response to drug treatments, continues to grow as understanding of the genome evolves, but much remains unknown. Invitrogen scientists will support research programs at the Pharmacogenomics Centre to improve the efficiency and speed with which researchers can identify single nucleotide polymorphisms (SNPs), differences in single base pairs that typically occur in more than one percent of the population.
“Pharmacogenomics holds the promise that drugs might one day be tailor-made for the individual,” said Michael Phillips, PhD, Associate Professor at the Université de Montréal and Director of Pharmacogenomics at the Montreal Heart Institute and Génome Québec. “We hope this collaboration enables us to make great strides in improving the tools and techniques available to researchers in this important field of study.”
“Integrating pharmacogenomics and biomarkers in a more personalized approach to healthcare holds great potential to improve the safety and efficacy of commonly used medications,” said Dr. Jean-Claude Tardif, Professor of Medicine at the Université de Montréal and Director of the Research Center at the Montreal Heart Institute.
Researchers at the Pharmacogenomics Centre are seeking to identify new SNPs within approximately 200 specific ADME/Tox-related genes that effect how a drug is metabolized by an individual. To identify these SNPs, researchers must analyze the ADME/Tox genes of a population of people through targeted medical resequencing. The collaboration focuses on ways to accelerate this process, thereby speeding the research.
“This collaboration offers Invitrogen the opportunity to work closely with thought leaders in the field of pharmacogenomics and to better understand this emerging area of research,” said Rob Bennett, Invitrogen’s Vice President of Advanced Sequencing Applications. “We are excited about combining our technologies and enzymology know-how with the Pharmacogenomics Centre’s knowledge of ADME/Tox genes.”
|
|
| Other News Items Published on the Wednesday, July 02, 2008 |
|
|